Analysis of EVs from patients with advanced pancreatic cancer identifies antigens and miRNAs with predictive value

Vannini, Ivan; Rossi, Tania; Melloni, Mattia; Valgiusti, Martina; Urbini, Milena; Passardi, Alessandro; Bartolini, Giulia; Gallio, Chiara; Azzali, Irene; Bandini, S.; Ancarani, Valentina; Montanaro, Lorenzo; Frassineti, Giovanni Luca; Fabbri, Francesco; Rapposelli, Ilario Giovanni

doi:10.1016/j.omtm.2023.05.009

Cited by 4 publications

(2 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More recently it has been demonstrated that EVs can convey not only proteins or lipids, but also microRNAs (miRNAs), pre-miRNAs, other non-coding RNAs, and mRNA [52], which are then translated in the target cell with consequent activation or inhibition of certain cellular processes, depending on the information transferred [53]. It is known that the miRNA-200 family can influence cancer biology in the context of pancreatic adenocarcinoma [54].…”

Section: Biology and Genesis Of Extracellular Vesiclesmentioning

confidence: 99%

Extracellular Vesicles, Circulating Tumor Cells, and Immune Checkpoint Inhibitors: Hints and Promises

Bandini,

Ulivi,

Rossi

2024

Cells

Self Cite

View full text Add to dashboard Cite

Immune checkpoint inhibitor (ICI) therapy has revolutionized the treatment of cancer, in particular lung cancer, while the introduction of predictive biomarkers from liquid biopsies has emerged as a promising tool to achieve an effective and personalized therapy response. Important progress has also been made in the molecular characterization of extracellular vesicles (EVs) and circulating tumor cells (CTCs), highlighting their tremendous potential in modulating the tumor microenvironment, acting on immunomodulatory pathways, and setting up the pre-metastatic niche. Surface antigens on EVs and CTCs have proved to be particularly useful in the case of the characterization of potential immune escape mechanisms through the expression of immunosuppressive ligands or the transport of cargos that may mitigate the antitumor immune function. On the other hand, novel approaches, to increase the expression of immunostimulatory molecules or cargo contents that can enhance the immune response, offer premium options in combinatorial clinical strategies for precision immunotherapy. In this review, we discuss recent advances in the identification of immune checkpoints using EVs and CTCs, their potential applications as predictive biomarkers for ICI therapy, and their prospective use as innovative clinical tools, considering that CTCs have already been approved by the Food and Drug Administration (FDA) for clinical use, but providing good reasons to intensify the research on both.

show abstract

Section: Biology and Genesis Of Extracellular Vesiclesmentioning

confidence: 99%

Extracellular Vesicles, Circulating Tumor Cells, and Immune Checkpoint Inhibitors: Hints and Promises

Bandini,

Ulivi,

Rossi

2024

Cells

Self Cite

View full text Add to dashboard Cite

show abstract

“…Implementing personalized screening strategies based on individuals' risk factors and genetic predispositions can help identify high-risk individuals and enable timely interventions. Collaborations between researchers and clinicians can identify predictive biomarkers that indicate the likelihood of response to specific treatments [244,245]. By understanding the genetic and molecular characteristics of pancreatic tumors, personalized treatment plans can be developed to optimize therapeutic responses.…”

Section: Precision Medicine and Personalized Carementioning

confidence: 99%

Pancreatic Cancer Health Disparity: Pharmacologic Anthropology

Wall,

Fuller,

Morcos

et al. 2023

Cancers

View full text Add to dashboard Cite

Pancreatic cancer (PCa) remains a formidable global health challenge, with high mortality rates and limited treatment options. While advancements in pharmacology have led to improved outcomes for various cancers, PCa continues to exhibit significant health disparities, disproportionately affecting certain populations. This paper explores the intersection of pharmacology and anthropology in understanding the health disparities associated with PCa. By considering the socio-cultural, economic, and behavioral factors that influence the development, diagnosis, treatment, and outcomes of PCa, pharmacologic anthropology provides a comprehensive framework to address these disparities and improve patient care.

show abstract

Preoperative treatment response prediction for pancreatic cancer by multiple microRNAs in plasma exosomes: Optimization using machine learning and network analysis

Ueda,

Takahashi,

Sakaniwa

et al. 2024

Pancreatology

View full text Add to dashboard Cite

Analysis of EVs from patients with advanced pancreatic cancer identifies antigens and miRNAs with predictive value

Cited by 4 publications

References 37 publications

Extracellular Vesicles, Circulating Tumor Cells, and Immune Checkpoint Inhibitors: Hints and Promises

Extracellular Vesicles, Circulating Tumor Cells, and Immune Checkpoint Inhibitors: Hints and Promises

Pancreatic Cancer Health Disparity: Pharmacologic Anthropology

Preoperative treatment response prediction for pancreatic cancer by multiple microRNAs in plasma exosomes: Optimization using machine learning and network analysis

Contact Info

Product

Resources

About